Eucaryotic viral vectors based upon the nonpathogenic parvovirus, adeno- associated virus (AAV) have recently emerged as promising vehicles for efficient gene transfer to a wide variety of cellular targets. AAV-based vectors are noncytopathic, possess wide species and tissue tropism, have high transduction efficiencies, stably integrate into host chromosomal DNA, and, unlike murine retrovirus vectors, efficiently transduce cells regardless of proliferating status. This latter characteristic is of critical importance for potential in vivo gene therapy, as subpopulations of mononuclear peripheral blood and pluripotential hematopoietic stem cells, highly attractive targets for gene therapy for a variety of diseases including AIDS, are normally quiescent. In this proposal, we will exploit the advantages of AAV-based vectors developed within our laboratory, and analyze gene transfer to both normal and malignant human marrow derived cells with efficiencies of greater than 70% will be presented. In addition, we will extend these results to purified subpopulations of primary marrow-derived cells, determine stability of vector-mediated transgene expression, characterize vector integration sites, and determine potential effects of transduction upon cellular function and multilineage development in vitro. In addition, we will directly compare AAV and retroviral vector-mediated transduction and transgene expression within these critical cellular populations. Finally, we will employ both AAV and retrovirus-based vectors encoding the neomycin phosphotransferase gene to genetically """"""""mark"""""""" a portion of human CD34+ peripheral blood stem cells (PBSCs) in the context of combination high dose chemoradiotherapy with autologous transplantation for indolent B-cell non- Hodgkin's lymphoma, and monitor for relapse with genetically marked cells. Such double labeling experiments within the same individual will allow a comparison of vector transduction efficiencies, effects upon hematopoietic multilineage development, and long term transgene expression in vivo. Information obtained from this work will further our understanding of and help to derive methodologies for optimal gene transfer to and stability of transgene expression within primary human marrow-derived cells both in vitro and in vivo, will provide important information about patterns of engraftment following PBSC transplantation, sites of relapse, the adequacy of """"""""conditioning"""""""" and stem cell purging regimens following autologous transplantation for hematologic malignancies, could facilitate AAV-based vector development for clinical gene therapy, and could provide the foundation for a gene therapeutic approach to the treatment of hematologic malignancies and AIDS.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
City of Hope National Medical Center
United States
Zip Code
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524

Showing the most recent 10 out of 364 publications